2026-04-14T06:23:51Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/135992025-10-24T08:28:26Zcom_2072_451660com_2072_378040col_2072_451662

Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis Martín Jiménez, Daniel Garcia-lliberos de miguel, Ainhoa Maza-Solano, Juan Moreno-Luna, Ramon Alobid, Isam Rodriguez-Iglesias, Miguel Calvo-Henriquez, Christian Izquierdo-Dominguez, Adriana Sinusitis DISEASES::Respiratory Tract Diseases::Nose Diseases::Paranasal Sinus Diseases::Sinusitis Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal PUBLICATION CHARACTERISTICS::Study Characteristics::Clinical Study::Clinical Trial::Controlled Clinical Trial::Randomized Controlled Trial::Pragmatic Clinical Trial ENFERMEDADES::enfermedades respiratorias::enfermedades nasales::enfermedades de los senos paranasales::sinusitis Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales CARACTERÍSTICAS DE PUBLICACIONES::características del estudio::estudio clínico::ensayo clínico::ensayo clínico controlado::ensayo clínico controlado aleatorizado::estudio clínico pragmático Biologic therapy; Chronic rhinosinusitis with nasal polyps; Dupilumab; Monoclonal antibody; Quality of life Dupilumab; Rinosinusitis crònica amb pòlips nasals; Teràpia biològica Dupilumab; Rinosinusitis crónica con pólipos nasales; Terapia biológica Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory condition that significantly impacts quality of life. Despite treatment advances, recurrence is common, prompting the exploration of novel therapies such as monoclonal antibodies targeting the type 2 immune response, notably dupilumab. This research aims to evaluate the real-world evidence (RWE) of dupilumab in treating severe CRSwNP, comparing sinonasal outcomes to those observed in randomized clinical trials. Significant improvements were noted, with the average SNOT-22 score reduction being 37.2 points post-dupilumab treatment. The nasal polyp size (NPS) showed an average decrease of 3.6 points. The analysis highlighted the practical effectiveness of dupilumab, emphasizing its benefit over conventional therapies in reducing NPS and improving nasal symptoms. The findings advocate for the integration of dupilumab into standard treatment protocols for severe CRSwNP, providing a robust alternative that could potentially reduce the high recurrence rates associated with current management strategies. This study underscores the utility of RWE in assessing the effectiveness of new medical treatments, suggesting that dupilumab offers substantial real-world benefits for patients suffering from this challenging condition. Funding for open access publishing: Universidad de Sevilla/CBUA. 2025-10-24T08:28:26Z 2025-10-24T08:28:26Z 2025-10-24T08:28:26Z 2025-09-03T11:15:30Z 2025-09-03T11:15:30Z 2025-02-05 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/13599 Current Allergy and Asthma Reports;25(1) https://www.doi.org/10.1007/s11882-025-01192-y Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Springer Scientia